[New observations support the significance of angiogenesis in myeloma].
Angiogenesis appears to be a prominent feature of many hematological disorders, in particular multiple myeloma. The remissions achieved when treating patients with advanced myeloma with the angiostatic drug thalidomide suggested that the disease might be angiogenesis-dependent. However, the mechanisms for the beneficial effect of thalidomide are, at this time, rather unclear, and may involve other effects beside angiostasis. Nonetheless, these and other observations have spurred an interest in angiogenesis that might lead to new concepts and treatment modalities. Here, an update concerning angiogenesis and multiple myeloma is presented.
Lundberg
L G
LG
Medicinkliniken, Södersjukhuset och institutionen Södersjukhuset, Karolinska institutet, Stockholm.
Lerner
R
R
Palmblad
J
J
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D009101:Multiple Myeloma / Q000098:blood supply* / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000276:immunology; D013792:Thalidomide / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D016207:Cytokines; D013792:Thalidomide